Ansfield F J, Davis H L, Ramirez G, Davis T E, Borden E C, Johnson R O, Bryan G T
Cancer. 1976 Jul;38(1):53-5. doi: 10.1002/1097-0142(197607)38:1<53::aid-cncr2820380110>3.0.co;2-c.
A previous study showed activity of megestrol acetate in advanced breast cancer; as a result the study was expanded. Of 101 patients treated with this compound, 26 (26%) met our criteria of improvement. The drug was well tolerated and produced no toxicity and, as opposed to androgens and estrogens, no endocrine effects were observed. Prior hormonal or cytotoxic compounds, including alkylating agents, did not appear to reduce the subsequent responsiveness to this potent progestational compound. We now include it, often as the initial hormonal trial in postmenopausal patients, in our sequential treatment of disseminated breast cancer because of its favorable therapeutic ratio.
先前的一项研究显示醋酸甲地孕酮在晚期乳腺癌中具有活性；因此该研究得以扩展。在接受该化合物治疗的101例患者中，26例（26%）符合我们的改善标准。该药物耐受性良好，未产生毒性，并且与雄激素和雌激素不同，未观察到内分泌效应。先前的激素或细胞毒性化合物，包括烷化剂，似乎并未降低后续对这种强效孕激素化合物的反应性。由于其良好的治疗比率，我们现在在转移性乳腺癌的序贯治疗中经常将其作为绝经后患者的初始激素试验药物。
